CRL

Business profile & competitive position

Charles River Laboratories International, Inc. operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry. It describes itself as a full-service, non-clinical global drug development partner, meaning it helps biopharmaceutical clients from target identification through non-clinical development and product release without running human clinical trials itself. Its business is organized into three reportable segments: Research Models and Services (RMS), which generated 21.1% of 2025 revenue; Discovery and Safety Assessment (DSA), which generated 59.8%; and Manufacturing Solutions, which generated 19.1%. Services span research model technologies, GLP and non-GLP safety assessment, discovery services, and manufacturing support.

The company runs more than 120 sites across more than 20 countries, giving it broad geographic reach and a diversified client base tied to global biomedical research. However, profitability metrics argue against pricing power in the current period. Net margin is -6.0% and return on equity is -7.7%, both negative despite the company’s scale and segment breadth. For equity investors, that combination is important: scale and a scientific service portfolio can form the foundation of a competitive position, but as of the latest figures they are not translating into positive earnings or returns on shareholder capital.

Financial posture

With a market capitalization of $14.5 billion and a current share price of $301.79, CRL carries a P/E ratio of -62.4. A negative P/E is the direct result of trailing losses and indicates that standard earnings-based valuation multiples are not currently applicable. The net margin of -6.0% and ROE of -7.7% reinforce that the business is in a loss-making posture, so valuation analysis relies more on top-line trajectory, margin recovery expectations, and strategic execution than on trailing earnings yield.

The stock’s beta is 1.40, meaning it has historically been more volatile than the broader market. Technically, the price sits above its 50-day exponential moving average of $277.53, with a relative strength index of 58.9, which is near neutral territory. The headline valuation of $14.5 billion therefore reflects the market’s view of a turnaround or growth-premium story rather than a current profitability premium.

Strategic priorities & outlook

According to the company’s most recent SEC 10-K filing, Charles River’s near-term operational focus is built around four main priorities. First, it intends to optimize its global footprint by closing or consolidating approximately 12 additional sites over the next two years, with the bulk of that work in the DSA and RMS segments. Second, it plans to integrate Discovery Services and Safety Assessment into one combined DSA organization, supported by a unified sales force and leadership structure. Third, it aims to establish itself as the scientific partner of choice by offering a comprehensive and integrated service portfolio that accelerates biomedical research and therapeutic innovation. Fourth, it continues to look for opportunities to expand Biologics Testing Solutions capabilities and facilities in the U.S. and Europe.

Recent execution examples support the strategic context. In January 2026 the company acquired certain assets of K.F. (Cambodia) Ltd., a provider of non-human primates, to support DSA supply operations and RMS third-party sales. For fiscal 2025, total revenue was $4.0 billion, with DSA contributing nearly 60% of that total. The site consolidation program, if executed efficiently, could improve segment margins; the DSA integration could make cross-selling easier; and the Cambodia acquisition is a direct move to secure research-model supply for a key customer need.

Macro & geopolitical exposure

As a Healthcare / Medical Diagnostics & Research services provider tied to non-clinical drug development, Charles River’s demand is driven by biopharmaceutical and biotechnology research spending. That makes it sensitive to broader funding conditions, including venture-capital flows into early-stage biotech, interest rates, and large-cap pharma R&D budgets.

Because its work includes safety assessment services subject to GLP and other regulatory standards, CRL is exposed to FDA, EMA, and other global regulatory regimes governing non-clinical testing data quality and study conduct. Trade policy matters as well: the January 2026 Cambodia non-human primate acquisition is one example of how research-model supply chains can cross borders, making animal health, export, and customs regulations relevant. Currency translation across more than 20 countries also affects reported revenue and costs. Additionally, animal-based research faces ongoing scrutiny from animal-welfare groups and evolving regulations, and any restriction on the use or transport of research models could ripple through RMS and DSA operations.

Recent developments

The most recent headlines bracket CRL’s upcoming autumn reporting period. On October 9, 2026, the company scheduled its third-quarter 2026 earnings release and conference call, according to Business Wire. On October 6, 2026, Business Wire reported that Charles River and Autolomous had partnered to transform laboratory execution systems, a move that fits the broader theme of integrating digital tools into the discovery and safety workflow.

Two Zacks stories from October 7, 2026, framed investor interest around the stock’s momentum. One compared Charles River with Progyny, Inc. (PGNY) on a value basis, while the other noted that CRL had gained 75.8% over the prior year and asked what was driving the rally. Taken together, the news cluster points to a company that is both reporting operational partnerships and attracting valuation and momentum commentary as it approaches its next earnings report.

Earnings behavior & post-earnings drift

Charles River has beaten earnings estimates in each of the last eight reported quarters, giving it a 100% beat rate over that span. The average earnings surprise across those quarters was 9.3%, and the average five-day price move after earnings has been 1.24% to the upside, classified as an “up” post-earnings drift. The current picture for the upcoming report is straightforward on the calendar: the next scheduled release is November 4, 2026, before market open, with a consensus EPS estimate of $2.96.

Recent quarterly behavior shows that beating estimates does not always guarantee a positive reaction. In the most recent report, filed August 5, 2026, CRL reported EPS of $3.02 against an estimate of $2.74, a 10.2% surprise. The stock rose 1.84% the next day and 9.07% over the following five sessions. The prior quarter, May 7, 2026, delivered a 5.1% beat with EPS of $2.06 versus $1.96, yet the stock fell 2.23% the next day and 12.42% over the following five sessions. Earlier, the February 18, 2026 quarterly beat (2.6% surprise) produced a 3.95% one-day gain and 6.05% five-day gain, while the November 5, 2025 report (4.7% surprise) brought a 1.9% one-day gain and 2.27% five-day gain. The takeaway for earnings watchers is that CRL has consistently cleared the official consensus by a wide average margin, but the market’s real expectation may be higher, especially given the recent 75.8% run-up and the negative current earnings profile.

For a deeper dive into the earnings setup, valuation debates, and whether analysts believe the margin recovery story is on track, readers should review the full institutional verdict and consensus estimate breakdown for CRL.